BioCina
Mark W. Womack is an experienced executive in the biopharmaceutical and management consulting sectors, currently serving as Chief Executive Officer at BioCina and a board member for LumaCina and NovaCina. Womack has held prominent leadership roles, including CEO of KBI Biopharma and Stelis Biopharma, achieving significant revenue growth and operational advancements in global biologics CDMO organizations. As Chief Business Officer at AGC Biologics, Womack drove substantial increases in business sales and led strategic initiatives following major acquisitions. Womack's earlier career includes executive positions in management consulting, notably at Brooks International and Celerant Consulting, where transformational achievements in revenue and client engagement were realized. Academic credentials include an Executive Education Program from Harvard Business School, a Master of Science in Organization Development from Chapman University, and a Bachelor of Science in Education from Southern Illinois University, Carbondale.
This person is not in any teams
This person is not in any offices
BioCina
BioCina is a global end-to-end biologics Contract Development and Manufacturing Organisation (CDMO), offering highest-quality, cost-effective cell line, process, analytical and formulation development, and cGMP clinical & commercial manufacturing for the microbial, pDNA and mRNA modalities. BioCina’s first facility in Adelaide, South Australia is a testament to the quality of its work. It has a rich history of developing and manufacturing both clinical and commercial drug substance, backed by most critical SME’s having an average tenure of 15+ years at the site. BioCina boasts an elite quality record having successfully passed regulatory inspections by the US FDA, EMA and Health Canada. It is licensed by the Australian TGA for cGMP manufacturing of bulk drug substance or active intermediates. Through a partnership with NovaCina, BioCina offers clients a highest-quality fill-and-finish solution. BioCina is proud to have clients globally, including U.S., Europe, and the Asia Pacific. Because BioCina is not a drug developer, it only serves clients' products. As one of the fastest growing companies in the biopharmaceutical industry across Australia, BioCina was awarded the 2024 South Australia “Emerging Business of the Year” award. Learn more at https://biocina.com.